일 | 월 | 화 | 수 | 목 | 금 | 토 |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | ||
6 | 7 | 8 | 9 | 10 | 11 | 12 |
13 | 14 | 15 | 16 | 17 | 18 | 19 |
20 | 21 | 22 | 23 | 24 | 25 | 26 |
27 | 28 | 29 | 30 | 31 |
- tern-601
- GPCR
- 제약바이오
- Efruxifermin
- Mash
- Pegozafermin
- 바이오스터디
- 노보노디스크
- gsbr-1290
- glp-1 비만
- structure therapeutics
- GLP-1 치료제
- Novo Nordisk
- danuglipron
- 2024 easl
- ct-996
- VKTX
- VK2735
- CAR-T
- lilly
- vk2809
- Viking Therapeutics
- tirzepatide
- GLP-1치료제
- orforglipron
- 비만치료제
- Nash
- CAR-T in autoimmune
- 경구용 glp-1
- GLP-1
- Today
- Total
목록CRBU (2)
제약바이오 츄롸이츄롸이!~
https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-presents-encouraging-clinical-data-cb-010 Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous ..
2024-05-09 Fate Therapeutics 실적발표 + 2024 ASGCT 학회 자료 발표https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-first-quarter-2024-financial-results Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates | Fate Therapeutics, Inc.The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockho..